Targeting GSK-3: a promising approach for cancer therapy?
Targeting GSK-3: a promising approach for cancer therapy? Read More »
Search Results for: F
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 16, 2025 08:30 ET Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes Read More »
Actuate Therapeutics Investor Event at ASCO to Discuss Elraglusib Phase 2 Topline Data in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
DATE: May 31, 2025TIME: 6:30 PM CDTLOCATION: Marriott Marquis Chicago, 2121 S Prairie Ave, Chicago, IL 60616 ACCESS THE REPLAY > DOWNLOAD THE TRANSCRIPT >
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
April 17, 2025 08:00 ET CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib
Expanded Access Policy
ACTUATE THERAPEUTICS EXPANDED ACCESS POLICY Actuate Therapeutics (“Actuate”) is dedicated to developing transformative clinical outcomes for patients suffering from advanced, hard-to-treat cancers, many of which are fatal with limited or no treatment options. We are committed to developing innovative therapies as quickly as our clinical programs, data review, and regulatory requirements allow. Through the inhibition
Expanded Access Policy Read More »
Actuate Therapeutics to be Added to Russell 2000® Index
November 26, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000® Index as part
Actuate Therapeutics to be Added to Russell 2000® Index Read More »
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
October 29, 2024 18:39 ET Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development Read More »
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
April 08, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The abstracts are
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting Read More »